Efficacy Study of Atorvastatin to Treat Variant Angina (ESAVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00620204|
Recruitment Status : Unknown
Verified April 2009 by Samsung Medical Center.
Recruitment status was: Recruiting
First Posted : February 21, 2008
Last Update Posted : April 6, 2009
|Condition or disease||Intervention/treatment||Phase|
|Angina Pectoris, Variant||Drug: atorvastatin||Phase 4|
Vasospastic angina is presented by myocardial ischemia with spasm of coronary artery accompanying chest pain or discomfort. The precise mechanisms have not been established, but a reduction in NO (nitric oxide) production, an imbalance between endothelium-derived relaxing and contracting factors,or an injury of endothelium have been suggested.
Impaired FMD(flow mediated endothelium-dependent vasodilation) in the brachial artery was demonstrated in vasospastic angina,and improvement of endothelial dysfunction with treatment of statin is documented in several studies.
So, we expect that statin treatment for vasospastic angina provide additional therapeutic effects via improvement of endothelial dysfunction.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||136 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy Study of Atorvastatin to Treat Variant Angina|
|Study Start Date :||January 2008|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||December 2010|
atorvastatin 40mg qd for 1 year
Other Name: Lipitor®
No Intervention: B
- Ergonovine provocation test 24hrs later after admission [ Time Frame: 1 year later ]
- Chest pain with EKG change during admission for 24hrs at 12mo. later (All medications are withheld for 48hrs. before admission) [ Time Frame: 1year later ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00620204
|Contact: Hyun-chul Gwon, MD,PhDfirstname.lastname@example.org|
|Korea, Republic of|
|Samsung Medical Center||Recruiting|
|Seoul, Korea, Republic of|
|Principal Investigator:||Hyun-chul Gwon, MD,PhD||Samsung Medical Center|